A 265 New York Assembly · 2025 Regular Session

Relates to the availability of opioid reversal agents

Summary

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agent approved by the federal food and drug administration.

Issues: ✓ Healthcare

Bill status passed 3 of 5 stages cleared

Introduction

Jan 2025

Committee Review

Jan 2026

Assembly Passage

Jan 2026

Senate Passage

Governor

Introduced Jan 8, 2025 Last action Jan 12, 2026

Maddy AI version diff · 1 comparison

What changed between versions

A265 → A265A · 4 edits

MODERATE

This bill amendment adds a new definition for 'Purchaser' and renumbers a section while adding new funding provisions for lower-cost opioid reversal products. The changes expand state coverage to include products cheaper than the highest-priced nasal naloxone, with the state bearing those costs rather than purchasers.

Scope change

The bill's scope remains focused on opioid reversal agent availability and pricing, but funding responsibilities now extend to cover lower-cost products in addition to higher-cost ones.

DEFINITION

Added new definition of 'Purchaser' to clarify which entities access opioid reversal drugs through the state standing order.

FISCAL

Added provision stating that the state will cover costs for opioid reversal products that are lower-priced than the highest-priced nasal naloxone product.

REQUIREMENT

Renumbered a section from subdivision 9 to subdivision 10 to accommodate the new funding provision.

TECHNICAL

Minor formatting changes including bill number formatting and page number updates.

Floor votes · Assembly Jun 13, 2025

How they voted

137–0

Passed · 13 other

Total votes 150

Jun 13, 2025

D Democratic103

92 Yea 11

89% Yea

R Republican47

45 Yea 2

95% Yea

Vote distribution

All Yea All Nay Mixed No data

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Amendments

Jan 12, 2026

Committee

REFERRED TO ALCOHOLISM AND SUBSTANCE USE DISORDERS

upper

Jan 12, 2026

Lower · Passed

PASSED ASSEMBLY

lower

Jun 13, 2025

Lower · Passed

PASSED ASSEMBLY

lower

Jun 13, 2025

Committee

REPORTED REFERRED TO RULES

lower

Feb 11, 2025

Committee

REPORTED REFERRED TO WAYS AND MEANS

lower

Jan 10, 2025

Lower · Passed

PRINT NUMBER 265A

lower

Jan 10, 2025

Lower · Passed

AMEND AND RECOMMIT TO ALCOHOLISM AND DRUG ABUSE

lower

Jan 8, 2025

Committee

REFERRED TO ALCOHOLISM AND DRUG ABUSE

lower

1 primary · 15 co-sponsors